Drug-Induced PML: A Global Agenda for a Global Challenge

The occurrence of severe adverse events such as progressive multifocal leukoencephalopathy (PML) has the potential to limit the benefits of highly efficacious medicines being developed to fulfill unmet clinical needs across therapeutic areas. Following an Expert meeting in London in July 2011 (http:...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2012-04, Vol.91 (4), p.747-750
Main Authors: Vinhas de Souza, M, Keller-Stanislawski, B, Blake, K, Hidalgo-Simon, A, Arlett, P, Dal Pan, G
Format: Article
Language:English
Subjects:
Animals
Antibodies, Monoclonal, Humanized - adverse effects
Biological and medical sciences
Global Health - standards
Humans
Leukoencephalopathy, Progressive Multifocal - chemically induced
Leukoencephalopathy, Progressive Multifocal - epidemiology
Leukoencephalopathy, Progressive Multifocal - prevention & control
London
Medical sciences
Natalizumab
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The occurrence of severe adverse events such as progressive multifocal leukoencephalopathy (PML) has the potential to limit the benefits of highly efficacious medicines being developed to fulfill unmet clinical needs across therapeutic areas. Following an Expert meeting in London in July 2011 (http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/09/WC500111562.pdf), a research agenda, highlighting methodological, clinical, and communication elements, to mitigate the risk and improve the management of drug‐induced PML has been agreed upon. Clinical Pharmacology & Therapeutics (2012); 91 4, 747–750. doi:10.1038/clpt.2012.4
ISSN:0009-9236
1532-6535
DOI:10.1038/clpt.2012.4